SLC5A2 and chronic kidney disease: Current therapies for CKD consist of renin-angiotensin system (RAS) blockade, mineralocorticoid receptor blockers, the endothelin 1 receptor antagonist, and the sodium-glucose transporter 2 (SGLT2) inhibitor.